ELV — Stock Film
STOCK FILMSCENE 1/11ELV · $401
Stock Expert AI presents
ELV
Elevance Health Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Elevance Health Inc. A quick introduction.

On the stock market since 2001, it operates in the world of health and science. It has 96,615 employees. Now — the numbers.

on the stock market since 2001
97K employees
$87B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $3 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 3%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
70%Health Benefits
Health Benefits 70%Carelon Services 30%
70% of all revenue comes from a single line: Health Benefits.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 9% a year over the last 4 years. Every year shown ended in profit.

$139B
2021
$157B
2022
$171B
2023
$177B
2024
$199B
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
87
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
45
weak

Clearly below the class average.

VALUATION
90
very strong

The price looks reasonable next to what the company earns.

GROWTH
81
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
61
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Executives are buying stock10/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark3/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 29% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 8% a year on average.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 41 buys and 26 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $6.86 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 45/100.

2
THE RISKS · 2/3
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.

3
THE RISKS · 3/3
Costs eat into the margin

Costs swallow the gains that sales growth brings in. Council score: 4/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, ELV sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ELV is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film